A bill to amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.

Bill 118 s 4785, also known as the "Direct-to-Consumer Drug Advertising Restriction Act," is a proposed amendment to the Federal Food, Drug, and Cosmetic Act. The main goal of this bill is to limit the advertising of prescription drugs directly to consumers.

If passed, this legislation would impose restrictions on pharmaceutical companies' ability to advertise their prescription drugs to the general public. Currently, these companies are allowed to promote their products through various media channels, such as television, radio, and print advertisements. However, this bill seeks to curb these practices in order to protect consumers from potentially misleading or harmful information.

The rationale behind this bill is to ensure that patients are receiving accurate and unbiased information about prescription drugs from their healthcare providers, rather than from advertisements that may prioritize sales over safety. By restricting direct-to-consumer drug advertising, supporters of the bill believe that patients will be better equipped to make informed decisions about their healthcare and medication options. Opponents of the bill argue that restricting direct-to-consumer drug advertising could limit patients' access to important information about potential treatment options. They also raise concerns about the impact this legislation could have on the pharmaceutical industry and its ability to promote new medications to the public. Overall, Bill 118 s 4785 represents a significant effort to regulate the advertising practices of pharmaceutical companies and prioritize the safety and well-being of consumers. The outcome of this legislation will likely have far-reaching implications for the healthcare industry and the way prescription drugs are marketed to the public.